Company
Built narrow, governed, and measurable
Decidian Intelligence is being built as a governed evidence-to-market control plane rather than an autonomous consulting replacement. The initial market is U.S. medical devices and software as a medical device, from concept through pre-submission readiness.
Problem
Why capable inventions stall
- Medical-product development is a chain of interdependent decisions, and the common failure is loss of context rather than lack of expertise.
- Work is distributed across consultants, CROs, counsel, laboratories, manufacturers, spreadsheets, and static decks, which produces inconsistent assumptions and weak decision lineage.
- Different pathways impose different evidentiary standards, so a single undifferentiated workflow is unsafe.
- Investors face the mirror image: uneven materials that force regulatory, clinical, reimbursement, technical, and capital risk to be reconstructed from scratch.
Positioning
Scope we hold ourselves to
Initial market
U.S. medical devices and SaMD, concept through pre-submission readiness
Commercial wedge
Paid portfolio pilot with an accelerator, CVC, venture studio, strategic, or development consultancy
Non-negotiables
Evidence lineage, ABSTAIN, hard safety and integrity gates, and named human authorization
Investor boundary
Research, permissioned discovery, diligence, and nonbinding interest only
Roadmap
Sequenced, and labelled as planning
Roadmap items are intentions, not commitments, and are presented as planning assumptions.
Now
U.S. device and SaMD triage, evidence graph, decision ledger, gates, and governed expert review.
Next
Deeper domain modules, investor mandate matching at portfolio scale, and outcome calibration.
Later
IVD, drug, biologic, and combination-product branches, which the data schemas already anticipate.
Talk to the team building it
We are direct about what exists today, what is planned, and what is not claimed.